112 related articles for article (PubMed ID: 20023269)
1. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases.
Solis LM; Raso MG; Kalhor N; Behrens C; Wistuba II; Moran CA
Am J Clin Pathol; 2010 Jan; 133(1):133-40. PubMed ID: 20023269
[TBL] [Abstract][Full Text] [Related]
2. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
[TBL] [Abstract][Full Text] [Related]
3. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
4. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
5. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
8. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
9. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
Onozato ML; Kovach AE; Yeap BY; Morales-Oyarvide V; Klepeis VE; Tammireddy S; Heist RS; Mark EJ; Dias-Santagata D; Iafrate AJ; Yagi Y; Mino-Kenudson M
Am J Surg Pathol; 2013 Feb; 37(2):287-94. PubMed ID: 23095504
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
[TBL] [Abstract][Full Text] [Related]
13. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.
Morita S; Yoshida A; Goto A; Ota S; Tsuta K; Yokozawa K; Asamura H; Nakajima J; Takai D; Mori M; Oka T; Tamaru J; Itoyama S; Furuta K; Fukayama M; Tsuda H
Am J Surg Pathol; 2013 Jun; 37(6):924-32. PubMed ID: 23629442
[TBL] [Abstract][Full Text] [Related]
14. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
[TBL] [Abstract][Full Text] [Related]
17. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
20. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
